BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 16872310)

  • 1. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
    Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
    Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
    Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
    Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
    Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
    Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.
    Kurashige T; Noguchi Y; Saika T; Ono T; Nagata Y; Jungbluth A; Ritter G; Chen YT; Stockert E; Tsushima T; Kumon H; Old LJ; Nakayama E
    Cancer Res; 2001 Jun; 61(12):4671-4. PubMed ID: 11406534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby].
    Xing BC; Yuan YH; Hu ZG; Liu YX; Han Y; Liu N; Chen WF; Wang Y
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1980-2. PubMed ID: 15730810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.
    Sato S; Noguchi Y; Wada H; Fujita S; Nakamura S; Tanaka R; Nakada T; Hasegawa K; Nakagawa K; Koizumi F; Ono T; Nouso K; Jungbluth A; Chen YT; Old LJ; Shiratori Y; Nakayama E
    Int J Oncol; 2005 Jan; 26(1):57-63. PubMed ID: 15586225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
    Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
    Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
    Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
    Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
    Vaughan HA; Svobodova S; Macgregor D; Sturrock S; Jungbluth AA; Browning J; Davis ID; Parente P; Chen YT; Stockert E; St Clair F; Old LJ; Cebon J
    Clin Cancer Res; 2004 Dec; 10(24):8396-404. PubMed ID: 15623618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1 expression and immunogenicity in prostate cancer patients.
    Gati A; Lajmi N; Derouiche A; Marrakchi R; Chebil M; Benammar-Elgaaied A
    Tunis Med; 2011 Oct; 89(10):779-83. PubMed ID: 22076902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
    Grah J; Samija M; Juretić A; Sarcević B; Sobat H
    Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.
    Kienstra MA; Neel HB; Strome SE; Roche P
    Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.